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Ionizing radiation to a cancer site has the ability to convert the irradiated tumor in an immuno-
genic hub. However, radiation is a complex modiﬁer of the tumor microenvironment and,
by itself, is seldom sufﬁcient to induce a therapeutically signiﬁcant anti-tumor immune
response, since it can also activate immune suppressive pathways. While several combi-
nations of local radiation and immunotherapy have been shown in pre-clinical models to
induce powerful anti-tumor immunity, the optimal strategy to achieve this effect remains
to be deﬁned. When used in vivo, radiation effects on tumors depend on the dose per
fraction applied, the number of fractions used, and the total dose. Moreover, the interplay
of these three variables is contingent upon the tumor setting studied, both in pre-clinical
and clinical applications. To enable repair of the collateral damage to the normal tissue,
radiation is usually given in multiple fractions, usually of 2 Gy. Generally, the use of larger
fractions is limited to stereotactic applications, whereby optimal immobilization reduces
inter- and intrafraction movement and permits a very conformal delivery of dose to the
target, with optimal exclusion of normal tissue. Translation of the partnership of radiation
and immunotherapy to the clinic requires a careful consideration of the radiation regimens
used.To date, little is known on whether different dose/fractionation regimens have a spe-
ciﬁc impact on the anti-tumor immune response. Most experiments combining the two
modalities were conducted with single fractions of radiotherapy. However, there is at least
some evidence that when combined with some speciﬁc immunotherapy approaches, the
ability of radiation to promote anti-tumor immunity is dependent on the dose and fraction-
ation employed. We critically review the available in vitro and in vivo data on this subject
and discuss the potential impact of fractionation on the ability of radiation to synergize with
immunotherapy.
Keywords: abscopal effect, fractionation, immunogenic cell death, immunotherapy, inflammation, in situ vaccine,
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INTRODUCTION
The therapeutic use of local ionizing radiation has been largely
guided by a strategy designed to achieve the goal of effectively
eliminating cancer cells while causing the least toxicity to nor-
mal adjacent tissues. The mechanisms underlying this strategy
were deﬁned by Withers as “The 4 R’s of Radiotherapy” (Withers,
1975), an helpful mnemonic reference to the factors thought to
determine the response of tissues to fractionated radiation: repair,
reassortment, repopulation, and reoxygenation. Steel added a
ﬁfth factor, radiosensitivity, in recognition of the fact that the
intrinsic vulnerability of different cancer cells differs markedly
(Steel et al., 1989).
The choice of fractionating (i.e., delivering the prescribed dose
in multiple fractions during separate radiation sessions, usually
once/day) derives from the necessity of enabling normal tissue to
repair during and after the course of radiation, to exploit the fact
that the tumor is at a disadvantage, since its repair machinery is
generally damaged. Based on extensive empirical experience, the
use of multiple daily doses of about 2 Gy to a total dose of approx-
imately 45–50 Gy, has evolved as a “standard” approach to control
microscopic disease for most tumor types, after surgical resection.
Generally, higher doses are required when the tumor is in place.
However, while total doses as low as 35–45 Gy are sufﬁcient to
control most lymphomas, in tumors considered relatively radio-
resistant such as melanoma or sarcomas, higher total doses are
necessary (Khan et al., 2011).
With the development of image-guided radiotherapy (IGRT)
the uncertainty about the target volume is markedly reduced,
permitting smaller and more conformal ﬁelds that reduce the
inclusion of normal tissue and allow the delivery of larger sin-
gle radiation doses with acceptable complications (Verellen et al.,
2007). Particularly when immobilization is assured, and the inter-
and intrafraction movement is minimized, single fractions have
shown to be both safe and effective. For brain metastases, for
example, stereotactic radiosurgery (SRS) utilizes single doses of
radiation in the order of 20 Gy, generally achieving control of the
lesion for the rest of the patient’s life (Frazier et al., 2010).
These considerations also apply to pre-clinical in vivo models.
Conversely, studies in cell lines inevitably avoid the issue of normal
tissue tolerance, and are generally conducted using a single dose
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approach. In vitro, the radiosensitivity of tumor cells is usually
determined by the clonogenic survival assay, which measure the
proliferative impairment of cells exposed to various single doses
of ionizing radiation, expressed as “surviving fraction”. At least in
the ﬁrst 24 h, there is generally little or no apoptotic response in
cancer cells of non-hematopoietic origin (Amundson et al., 2008).
In fact, depending on the cell cycle phase at the time of irradiation,
carcinoma cells that have lost clonogenic ability have been shown
to die by necrosis or by other forms of cell death and after a few
or several divisions, up to at least 10 generations post-irradiation
(Chu et al., 2002).
Similar to the clinical setting, when radiation is applied in
experimental tumors, neoplastic cells, tumor stroma and some
adjacent normal tissue are also exposed. In vivo, the radiosensi-
tivity of a tumor depends on the complex interaction between
the intrinsic sensitivity of the cancer cells and that of the tumor
microenvironment, with hypoxia representing a major modula-
tor of radiosensitivity (Vaupel, 2004). Importantly, the results
depend on the integrity of the animal immune system. Stone
et al. (1979) showed that the radiation dose required to cure
50% of the tumors (TCD50) was more than twice as high in
mice lacking T cells, providing the ﬁrst evidence that radiother-
apy induces anti-tumor T cell responses that contribute to tumor
control.
RADIATION-INDUCED CELL DEATH, IMPLICATIONS FOR
IMMUNOTHERAPY COMBINATIONS
There are at least two important implications of the kinetics of
cell death post-radiation. The ﬁrst is that most irradiated cells
survive at least for a limited time, during which they undergo
a stress response, transmitted through multiple signal transduc-
tion pathways to the surrounding tissue. This process is associated
with changes in speciﬁc gene expression that depend on the tissue
of origin, the genetic background of the host, the p53 status of
the tumor and the radiation type and regimen used (Amundson
et al., 1999, 2008; Tsai et al., 2007b; John-Aryankalayil et al., 2010).
Among genes up-regulated following radiation are those control-
ling expression of growth factors, cytokines, chemokines, and
cell surface receptors that modulate the interaction of the tumor
with the immune system (Demaria and Formenti, 2007; Formenti
and Demaria, 2008). As an important modiﬁer of the tumor
microenvironment, radiation can change tumor immunogenic-
ity with consequences outside of the irradiated ﬁeld (Formenti
and Demaria, 2009).
The second implication is that, after radiation exposure, among
the cells programmed to die, the type of death is highly variable,
spanning from apoptosis and necrosis to autophagy and mitotic
catastrophe. Importantly, radiation has been shown to induce an
immunogenic cell death (ICD), characterized by three molecu-
lar signals that promote uptake of dying cells by dendritic cells,
cross-presentation of the tumor-derived antigens to T cells, and
activation of anti-tumor T cells: exposure of calreticulin on the
tumor cell surface, release of high-mobility group protein B1
(HMGB1), and release of ATP (Apetoh et al., 2007; Obeid et al.,
2007a,b; Ghiringhelli et al., 2009). In vitro calreticulin exposure
in a mouse colon carcinoma was shown to occur after a single
75 Gy dose (Obeid et al., 2007a), an unrealistic dose to translate
to the clinic. However, HMGB-1 release in the EL4 lymphoma
occurred after a single 10 Gy dose (Apetoh et al., 2007): cur-
rently, little is known about the exact dose-dependency of these
effects.
Overall, available evidence suggests that local radiation at clini-
cally therapeutic doses always elicits some activation of the innate
and adaptive immune system (McBride et al., 2004). However, the
proportion of tumor cells undergoing ICD is variable. Similarly,
variable is the type of remodeling of the tumor microenvironment
after radiation, for example, in terms of recruitingmore functional
DC rather than immunosuppressive myeloid cells and regulatory
T cells. The results of this balance are likely to determine the abil-
ity of radiation to convert the cancer in an effective in situ vaccine
(Formenti and Demaria, 2012). Understanding this balance has
relevant clinical implications, with the potential to expand the
application of ionizing radiation.
This review will discuss the available, albeit limited data in sup-
port of an effect of dose and fractionation of local radiotherapy in
determining successful anti-tumor immunity. We will deliberately
exclude discussing the immunosuppression caused by total body
radiation, which is largely due to different mechanisms (i.e., dele-
tion of the more sensitive naïve T cells and other cells; McFarland
et al., 2012).
EXPERIMENTS TESTING SINGLE FRACTIONS OF RADIATION
Several studies have shown that ionizing radiation induces or up-
regulates cell surface molecules involved in recognition and/or
killing of tumor cells by cytolytic T cells (CTL). These include
major histocompatibility class I molecules (MHC-I), Fas/CD95,
intercellular adhesionmolecules-1 (ICAM-1), andNKG2D ligands
(Hareyama et al., 1991; Gaugler et al., 1997; Chakraborty et al.,
2003, 2004; Garnett et al., 2004; Gasser et al., 2005; Kim et al., 2006;
Newcomb et al., 2006; Reits et al., 2006). Inmost studies, escalating
doses of radiation, delivered in a single fraction, were tested on one
or a few cell lines of mouse or human origin.
In one of the most comprehensive studies, Garnett et al. (2004)
analyzed a panel of 23 human tumor cell lines of colon, lung,
and prostate origin for the effect of radiation on expression of
MHC-I, Fas, ICAM-1, and two tumor-associated antigens, carci-
noembryonic antigen (CEA) and mucin-1 (MUC-1). Exposure to
a single dose of 10 or 20 Gy induced the up-regulation of at least
one molecule in 91% of the cell lines (Garnett et al., 2004). These
data indicate that phenotypic changes, which may impact tumor
immunogenicity, are common post-radiation. They also highlight
the variability among tumors in terms of which molecules are
up-regulated. In this respect, the frequent loss or alterations of
genes encoding one or more of the molecules required for the
generation and assembly of MHC-I in cancer cells, precludes an
effective MHC-I up-regulation in response to radiation (Chang
and Ferrone, 2007) .
Reits et al. (2006) demonstrated in vitro and in vivo up-
regulation of MHC-I, and provided important insight in the
regulationof thesemolecules by radiation. Humanmelanomacells
exposed to a single dose of radiation increased MHC-I expres-
sion in a dose- and time-dependent manner: while 1 Gy did
not cause any signiﬁcant increase above baseline, 4 Gy slightly
increased MHC-I expression. Ten and 25 Gy caused a larger, over
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twofold, increase at 72 h. A slightly faster kinetic was observed after
25 Gy (Reits et al., 2006). They demonstrated that surface MHC-
I expression is enhanced in response to increased availability of
antigenic peptides for loading on MHC-I.Within the ﬁrst 4 h after
radiation, an increased degradation of cellular proteins damaged
by radiation-induced radicals occurs, and the process evolves to
activate mTOR. mTOR activation results in increased protein syn-
thesis and enhances defective ribosomal products. Interestingly, a
change in the repertoire of peptides displayed on surface MHC-I
molecules was noticeable, with appearance of new peptides not
present in non-irradiated tumor cells, reﬂecting protein synthe-
sis in response to DNA damage (Reits et al., 2006). Employing the
mouse MC38 colon carcinoma, Reits et al. (2006) showed that sin-
gle doses of 8, 10, or 20 Gy enhanced MHC-I expression for up
to 11 days: despite the fact that most cells survived irradiation,
a larger proportion was eventually eliminated by tumor-speciﬁc
CTL than those observed in non-irradiated controls. Importantly,
in vivo there was a synergy between tumor irradiation with a sin-
gle dose of 10 Gy and adoptive transfer of CTL. The majority of
tumors receiving the combination therapy regressed. In contrast,
radiation alone only slightly inhibited tumor growth, and CTL
transfer by itself had no effect.
Overall, the data suggest that even a radiation regimen relatively
ineffective at killing tumor cells and inhibiting tumor growth may
still sensitize the tumor to rejection by CTL, if sufﬁcient signaling
to repair, triggering mTOR activation, is produced.
Many pro-inﬂammatory cytokines and chemokines are
induced by irradiation of tumors and/or normal tissues. In vivo,
this is often a reﬂection of the type of inﬂammation that develops
as an acute or chronic response to the radiation-induced tissue
damage (Hong et al., 1999; Johnston et al., 2002; Lugade et al.,
2008). In vitro, induction of interleukin (IL)-1β was detected as a
rapid response to irradiation with a single dose of 20 Gy in normal
mouse spleen cells and leukemia cells (Ishihara et al., 1993). IL-
1β was also induced in human alveolar macrophages by a single
dose of 2 Gy (Degenhardt et al., 2006). IL-1β secretion requires
processing by caspase-1, which is activated by the NLRP3 inﬂam-
masome (Barker et al., 2011). Death of normal or tumor cells
that occurs by apoptosis associated with autophagy is required
to activate the inﬂammasome in macrophages and dendritic cells
(Michaud et al., 2011; Petrovski et al., 2011). Activation of the
inﬂammasomeandproductionof IL-1βwere identiﬁed as essential
events for the optimal activation of anti-tumor T cells following
treatment-induced ICD(Ghiringhelli et al., 2009). Given that radi-
ation can induce macrophages to release IL-1β in the absence of
tumor cells in vitro (Degenhardt et al., 2006), it is intriguing to
consider whether, in vivo, this effect may contribute to the devel-
opment of anti-tumor immunity after radiotherapy. This could be
especially relevant among cancer cells with impaired autophagy
pathways that are unable to generate all necessary signals for ICD
(Michaud et al., 2011).
Radiation can also directly stimulate the production of some
cytokines and chemokines fromcancer and/or tumor stromal cells.
For example, tumor necrosis factor-alpha (TNF-α) was produced
by human sarcoma cells exposed to a single dose of 5 Gy (Hallahan
et al., 1989). CXCL16 was induced in vitro in human breast cancer
cells and murine mammary, prostate, and colon carcinoma cells
by a single dose of 12 Gy (Matsumura et al., 2008; Matsumura
and Demaria, 2010). Induction of CXCL16 in mouse breast can-
cer cells was dose-dependent, starting at 2 Gy and reaching a
plateau between 6 and 12 Gy. Interestingly, maximal secretion
was reached after 6 Gy in one tumor but it required >12 Gy in
another, suggesting inter-tumor variability in the response (Mat-
sumura et al., 2008). Importantly, CXCL16 induction by local
radiotherapy with two doses of 12 Gy was also seen in vivo in
the mouse 4T1 mammary carcinoma, and shown to enhance
tumor inﬁltration by CXCR6+ effector CD8 T cells (Matsumura
et al., 2008).
Radiation can also induce the activation of anti-inﬂammatory
pathways. For instance, the pleiotropic immunosuppressive
cytokine transforming growth factor-beta (TGF-β) was activated
by radiation from its latent form after a single dose of 5 and
10 Gy (Barcellos-Hoff, 1993; Barcellos-Hoff et al., 1994; Jobling
et al., 2006). TGF-β suppresses the function of dendritic cells and
effector CD8 T cells, while promoting the conversion of CD4 T
cells into regulatory (Treg) cells (Wrzesinski et al., 2007). There-
fore, increased activated TGF-β post-radiation could hinder the
development of anti-tumor T cells and their function in the
tumor. Strategies to inhibit TGF-β post-radiation are currently
investigated in the clinic.
EXPERIMENTS TESTING DOSE FRACTIONATION
Fewer studies have addressed the effects of dose fractionation. In
vitro, when mouse B16 melanoma cells were exposed to multiple
daily doses of 2 Gy, 5 days/week up to a total dose of 50 Gy, mim-
icking clinical protocols, MHC-I expression was increased after
the second week, when the total dose amounted to 20 Gy (Hauser
et al., 1993). The increased expressionwas stable for at least 5weeks
after the last radiation fraction, and was associated with increased
expression of MHC-I heavy chain mRNA, suggesting the possi-
bility that different mechanisms than activation of mTOR (Reits
et al., 2006) are responsible for MHC-I up-regulation induced by
different radiation regimens.
The contribution of the different mechanisms of MHC-I
up-regulationby radiationdescribed in vitro remains to bedemon-
strated in vivo. In the B16 murine melanoma model Lugade et al.
(2008) found that MHC-I up-regulation after in vivo irradiation
with a single dose of 15 Gy required host-produced interferon-
gamma (IFN-γ) since it was not seen in IFN-γ deﬁcient mice.
This suggests that signaling by host cells may dominate in vivo,
shifting the focus from tumor cell-intrinsic responses to the
cross-talk between irradiated tumor cells and the local immuno-
logical microenvironment. Consistently, we found that the tumor
microenvironment in vivo alters the phenotype of cancer cells,
as well as their response to radiation. 4T1 mouse breast can-
cer cells had increased baseline expression of MHC-I in vivo as
compared to cells cultured in vitro, but they lost expression of
NKG2D ligands. Radiation increased expression of MHC-I on
4T1 cells in vitro but not in vivo, while ICAM-1 and Rae-1,
one of the NKG2D ligands, were increased by radiation in vivo
(Ruocco et al., 2012).
Radiation can also up-regulate or induce other molecules that
enhance the efﬁciency of cancer cell killing by CTL. For example,
Fas was induced in an in vivo mouse model of colon carcinoma
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after a single dose of 8 Gy or after four fractions of 2 Gy given
in consecutive days (Chakraborty et al., 2003, 2004). The two
radiation regimens combined with vaccines (vaccinia and avipox
recombinant vaccines expressing CEA and three T cell costimula-
tory molecules) achieved comparable tumor regression, whereas
either vaccine or radiation as monotherapy failed to signiﬁcantly
affect tumor growth (Chakraborty et al., 2004). Therefore, Fas
expression appears to occur with either single or fractionated RT
and results in a clinically detectable effect.
It is tempting to speculate whether this radiation-induced
increase in the expression of MHC-I, Fas, or other molecules con-
tributes to better tumor regression particularly in patients with
pre-existing higher levels of natural anti-tumor T cells (Galon
et al., 2006; Vesely et al., 2011; Wang et al., 2012). In other words, a
pre-existing anti-tumor immunity may result to be a predictor for
response to radiotherapy.
Using the B16 mouse melanoma, Lee et al. (2009) showed that
tumor growth delays obtained with a single dose of 20 Gy or three
fractions of 15 Gy were comparable, and almost abrogated by
CD8 T cell depletion, suggesting that both regimens can promote
cross-priming of anti-tumor T cells. In contrast, 5 Gy × 4 given
over a 2-week interval, showed inferior tumor growth inhibition,
although the contribution of CD8 T cells to this effect was not
investigated. In the same model, Lugade et al. (2005) had previ-
ously shown that cross-priming of T cells against tumor antigens
was induced in the draining lymph nodes after irradiation with a
single dose of 15 Gy or 3 Gy × 5. While both regimens induced
the activation and expansion of anti-tumor T cells, and increased
VCAM-1 expression on tumor endothelium and T cell inﬁltration
in the tumor, the regimen of 3 Gy × 5 failed to cause a signiﬁcant
inhibition of tumor growth (Lugade et al., 2005).
These results are in contrast with our ﬁndings with radiation
and anti-CTLA-4. Comparing three radiation regimens, 20Gy× 1,
8 Gy × 3, and 6 Gy × 5, we demonstrated a marked difference
between single dose and fractionated regimens, in the ability to
synergize with anti-CTLA-4 antibody treatment and induce an
anti-tumor immune response able to inhibit tumor locally, at the
irradiated site, and systemically (Dewan et al., 2009). Two poorly
immunogenic tumor models not expressing model antigens, a
mammary and a colorectal carcinoma, respectively syngeneic to
mice of different genetic background were studied. All three reg-
imens had similar ability to cause growth delay of the irradiated
tumor, without affecting the growth of a tumor outside of the
radiation ﬁeld. While anti-CTLA-4 by itself or in combination
with a single 20 Gy dose was ineffective, when combined with
the two fractionated regimens it signiﬁcantly improved inhibi-
tion of both the irradiated and tumors outside the irradiated
ﬁeld (abscopal response, from ab-scopus, i.e., outside the tar-
get). The effectiveness of the generated anti-tumor response was
highest with 8 Gy × 3, with 80% of the irradiated tumors and
40% of the tumors outside the ﬁeld regressing completely. Since
anti-CTLA-4 antibody is known to be ineffective against poorly
immunogenic tumors but to synergize with vaccination in induc-
ing anti-tumor immunity (Peggs et al., 2008), these data imply
that radiation used as single dose of 20 Gy failed to convert the
tumor into an in situ vaccine. These results suggest that, for the
combination with anti-CTLA-4, there may be an optimal window
for the pro-immunogenic effects of radiation, with a hypofrac-
tionated regimen providing the best results. We are currently
performing genome-wide gene expression analyses to investigate
the changes that distinguish the two regimens and may be respon-
sible for the interaction of the irradiated tumor with the immune
system.
Overall, while some degree of immunization against the tumor
may be always promoted by radiotherapy, the magnitude of this
effect and the overall changes in the tumor toward a more or
less immunosuppressive environment are likely to be the deter-
minants of treatment success. Pre-clinically, a speciﬁc dose and
fractionation may be superior to another, and it appears to be
model-dependent. In this regard, Schaue et al. (2012) recently
proposed that the relative ability of a given radiation regimen to
increase cross-priming while not increasing Treg cell numbers will
determine its pro-immunogenic effect. They identiﬁed ahypofrac-
tionated regimen with two fractions of 7.5 Gy as providing the best
compromise between promotion of T cell cross-priming to tumor
antigens versus relative induction of Treg (measured as increased
Treg cell numbers) in themouse B16melanomamodel. Themech-
anisms underlying Treg cells increase by radiation as well as their
suppressive function in this setting remain to be clariﬁed (Qu et al.,
2010; Billiard et al., 2011; Kachikwu et al., 2011).
LEARNING FROM CLINICAL EXPERIENCE
Local radiation by itself may occasionally be able to elicit the
development of a sustained anti-tumor immune response able to
control tumor locally and systemically as suggested from reported
cases of abscopal effects, i.e., tumor responses outside of the ﬁeld of
radiation in cancer patients receiving radiation to one site (Mole,
1953; Ehlers and Fridman, 1973; Rees and Ross, 1983; Ohba et al.,
1998; Wersall et al., 2006). In one report, 4 of 28 patients with
metastatic renal cell carcinoma showed abscopal effects: in two
patients after receiving 8Gy×4 to theprimary tumorby SBRT,and
in another two patients after two doses of 15 Gy to a metastatic site
(Wersall et al., 2006). The lack of data about the immune response
in these patients makes it difﬁcult to reach any deﬁnite conclusion
about the involvement of the immune system.
However, immunological changes associated with an abscopal
response were recently reported in a melanoma patient treated
with local radiotherapy and ipilimumab, the anti-CTLA-4 anti-
body approved for clinical use (Postow et al., 2012). The patient
received radiotherapy in three fractions of 9.5 Gy, a regimen com-
parable to the regimen (8 Gy × 3) showing optimal synergy with
anti-CTLA-4 therapy inmouse tumormodels (Dewan et al., 2009).
The patient displayed a complete clinical remission of the primary
andmetastatic sites, despite previous progressionwith ipilimumab
therapy when given alone.
Abscopal responses were also reported in a clinical study of
patients with low-grade B cell lymphoma treated with 2 Gy × 2
to a single tumor site that was injected with a Toll-like receptor 9
(TLR9) agonist PF-3512676, an activator of B cells and antigen-
presenting cells (Brody et al., 2010).
It has been speculated that conventional fractionated radiother-
apy with multiple fractions of about 2 Gy is immunosuppressive
(Lee et al., 2009). However, clinical data disproves this con-
tention: Gulley et al. (2005) administered a poxviral vaccine
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encoding prostate-speciﬁc antigen (PSA) to 17 prostate cancer
patients undergoing radiotherapy with total external beam dose
≥70 Gy given in 1.8 to 2.0 Gy per fraction. PSA-speciﬁc T
cell responses were analyzed before radiotherapy, immediately
after and 3 months later. Eight patients showed blunted immune
responses to PSA following radiotherapy, six had stable responses,
and in two patients the response was increased after radiotherapy
(Gulley et al., 2005). Moreover, six out of eight patients evalu-
ated showed the development of T cell responses against tumor
antigens not present in the vaccine, suggesting that radiation
promoted the activation of T cells against other tumor antigens
(Gulley et al., 2005).
Finally, a recent report in patients with metastatic melanoma
and renal cell carcinoma treated with SBRT given in one, two, or
three doses of 20 Gy, in combination with high dose IL-2 showed a
response rate innon-irradiated lesions (abscopal responses) higher
than expected with IL-2 alone (Seung et al., 2012).
Overall, while emerging clinical data conﬁrm at least some
of the observations in experimental models, they fail to provide
indications about the best radiation regimen to be used to elicit
anti-tumor immune responses. One limitation in interpreting
these results is the lack of randomized studies comparing radiation
regimens for their ability to synergize with immunotherapy.
CHALLENGES AND FUTURE DIRECTIONS
While data about the effects of radiation on various immune
parameters is rapidly accumulating in experimental model, poten-
tial pitfalls exist in correctly interpreting the results. For instance,
tumors which are more immunogenic, for example, engineered
to express a “model” antigen such as ovalbumin (OVA), tend
be more susceptible to immune-mediated rejection than poorly
immunogenic tumors. The latter, however,much better mimic the
reality of clinical cancer patients, who generally are diagnosed after
immune-selection had edited out more immunogenic antigens
(Vesely et al., 2011).
Tumor size and intrinsic radiosensitivity also affect the degree
of response to a tested intervention. Importantly, pre-clinical evi-
dence of an induced immune response based on re-challenging
with the same experimental tumor initially used to immunize
remains only an indirect predictor for a successful therapeu-
tic paradigm. In fact, in the clinic the endpoint is control of
pre-existing micro- or macrometastatic foci and impact on sur-
vival, a much harder goal to achieve. Additionally, different
immunosuppressive mechanisms (e.g., Treg cells versus myeloid-
derived suppressor cells) may dominate the models compared.
This variability is likely to also exist in different clinical tumor
types.
For example, there is some evidence that radiationpromotes the
immunosuppressive function of macrophages (Tsai et al., 2007a).
On theother hand, a recent report shows that radiotherapy induces
the production of type I IFNbymyeloid cells inﬁltrating the tumor
andpromotes the development of anti-tumor immunity (Burnette
et al., 2011). Whether these contrasting effects are dependent on
the radiation regimen or the tumor model employed remains to
be established.
Therefore, conclusions about the relative efﬁcacy of different
radiation regimens can only be made by direct comparison using
the same, unmodiﬁed tumor model and testing the combination
with the same immunotherapy strategy.
Finally, since we are witnessing a paradigm change in the use
of radiotherapy that promises to revolutionize patient treatment
(Formenti and Demaria, 2012), the development of a common
language is essential. A cautious choice of terminology is war-
ranted. For instance, terms as “ablative” should be reserved to
settings where a complete elimination of tumors is achieved. In
addition, attributes like “conventional” and “standard” need to be
carefully justiﬁed. This is especially needed since radiation biology
is becoming a point of encounter for other specialties.
CONCLUSIONS
Tumor rejection by the immune system involves a common ﬁnal
pathway mediated by the activation of a speciﬁc set of genes
(Wang et al., 2008). These include the coordinate activation of
IFN-stimulated genes and immune effector functions. However,
multiple factors serve as checkpoints in the pathway toward
this canonical response (Wang et al., 2012). In order to identify
the radiation regimens that can best overcome the checkpoints
toward immune-mediated tumor rejection, it should be possible
to identify a gene signature that deﬁnes the pro-immunogenic
effects of radiation. Such signature is the result of the interaction
between the pre-existing tumor microenvironment, the genetic
predisposition of the host, and the radiation regimen used.
In support of this concept, Tsai et al. (2007b) reported distinct
molecular responses of human breast, prostate, and glioma tumor
cells exposed to single dose (10 Gy) versus fractionated (2 Gy × 5)
radiation in vitro and in vivo. Importantly, selective up-regulation
of IFN-related genes by fractionated but not single dose radiation
was seen in all three cell lines (Tsai et al., 2007a). In addition, a
comparison of the response of the prostate carcinoma cell line
to single dose and fractionated radiation in vitro versus in vivo
showed that there was no overlap between the four conditions,
indicating that the gene response to radiation is highly dependent
on the microenvironment and the regimen (Tsai et al., 2007a).
Although in this study the recipient mice were T cell deﬁcient,
they had an intact innate immunity, which is likely to play a key
role in the initial triage of tissue damage. John-Aryankalayil et al.
(2010) showed in humanprostate cancer cells that genes regulating
immune and stress response, cell cycle, and apoptosis were signif-
icantly up-regulated by multi-fractionated radiation compared to
single-dose radiation.
Although the optimal pro-immunogenic radiation regimen
may not necessarily be the same for all tumor types or settings,
a signature that deﬁnes the pro-immunogenic effects of radiation
could be used to optimize protocols of radiation and immunother-
apy in different tumor types, as well as to predict response to
treatment in different patients.
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